Specifically, we hypothesize that PAD patients with significant risk factors for systemic cardiovascular events may upregulate IGFBP-1 expression as a mechanism to support metabolic homeostasis, vascular repair, and endothelial function to reduce MACE risk. Here, IGFBP1 is linked to peripheral arterial disease.